LAFOV PET/CT improves predictive dosimetry and molecular imaging in theranostics, enhancing patient personalization.
Long-axial field-of-view (LAFOV) PET/CT has the potential to redefine the role of molecular imaging in theranostics by making multiparametric whole-body (MPWB) imaging and predictive dosimetry more clinically feasible. Compared to conventional PET systems, LAFOV scanners provide dramatic gains in sensitivity and coverage, allowing dynamic acquisitions, delayed imaging, and dual-tracer protocols within clinically feasible workflows. These advances supply the quantitative data required for physiologically based pharmacokinetic (PBPK) modeling and the creation of theranostic digital twins, supporting true personalization of radiopharmaceutical therapy.
No takes yet. Share an insight, caveat, or question.
Esquinas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: